曲美布汀联合双歧三联活菌治疗肠易激综合征的Meta分析

目的评价曲美布汀联合双歧三联活菌药物治疗肠易激综合征的有效性。方法通过计算机检索中国期刊全文数据库、中国科技期刊全文数据库、数字化期刊数据库(万方)、中国生物医学文献数据库,检索时限均为从建库至2011年2月,并手工检索相关参考文献,对检索到的文献进行筛选和质量评价,纳入了9个曲美布汀联合双歧三联活菌治疗肠易激综合征的RCTs(随机对照试验),再应用RevMan 5.0对这9篇RCTs研究结果进行Meta分析。结果曲美布汀联合双歧三联活菌治疗肠易激综合征的显效率和总有效率均高于单用曲美布汀治疗肠易激综合征,合并RR值分别为1.29和1.20,95%可信区间分别为1.15～1.45和1.14～1.27。结论曲美布汀联合双歧三联活菌治疗肠易激综合征比单用曲美布汀治疗肠易激综合征疗效更好。

Meta-analysis of the effects of combination of Trimebutine Maleate and BifidTripleViable to treat Irritable Bowel Syndrome (IBS)

Objective To compare the effects of combination of Trimebutine Maleate and BifidTripleViable vs.Trimebutine Maleate.to treat irritable bowel syndrome（IBS）.Methods By searching CNKI,Chinese Science and Technology Academic Journal（VIP）,CBM and WanFang Data,The results of 9 studies about the effects of combination of Trimebutine Maleate and BifidTripleViable in treatment of IBS were performed using Meta-analysis by RevMan 5.0.Results Both significant effective and total effective rate of combination of Trimebutine Maleate and BifidTripleViable in treatment of IBS were significantly higher than Trimebutine Maleate.Pooled RR of the effectual rate and total effective rate were 1.29 and 1.20 respectively,and their 95% confidence intervals were 1.15~1.45 and 1.14~1.27 respectively.Conclusion The effect of combination of Trimebutine Maleate and BifidTripleViable in treatment of IBS was better than Trimebutine Maleate.